AMX0035 Extended Patients’ Survival By More Than 10 Months

AMX0035 Extended Patients’ Survival By More Than 10 Months

Treatment with AMX0035 significantly extended the median survival of amyotrophic lateral sclerosis (ALS) patients by more than 10 months compared with a placebo, a new analysis of the Phase 2/3 CENTAUR clinical trial indicates. That survival difference was even greater in patients who continued to receive AMX0035 in the open-label…

The Straw That Breaks the Camel’s Back

A couple weeks ago, one of our toilet tanks developed a crack and started leaking. I turned off the water, and while we waited for a new tank to arrive, we filled a bucket with water from the tub to flush the toilet or used the other bathroom. On Saturday,…

Wave Life’s WVE-004 Shows Proof of Concept in Cell, Mouse Models

WVE-004, Wave Life Sciences‘ experimental therapy for people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, has demonstrated proof-of-concept efficacy in cell and animal models, a new study shows. The nucleic acid-based therapy was able to “potently” reduce the toxic RNA molecules and small proteins…

Why We Still Need More ALS Awareness

Did you know that May has been ALS Awareness Month for the past 30 years? Yes, that’s right, 30 years. Some probably think ALS awareness activities began in 2014 with the ice bucket challenge. At least that’s when many first pronounced the letters A-L-S before dumping a bucket of water…

Living With ALS Takes Courage

Editor’s note: This column discusses suicide. Please find resources for help at the end of the column. In the “Safety Training” episode of the sitcom “The Office,” Michael Scott, the boss, wants to prove that working upstairs in the office is just as risky as working in the…